Galapagos raises ?1.2 million through warrant exercises
(Thomson Reuters ONE) -
Mechelen, Belgium; 2 October 2015 - Galapagos NV (Euronext & NASDAQ: GLPG)
announced a share capital increase arising from warrant exercises.
As a result of warrant exercises, Galapagos issued 118,260 new ordinary shares
on 25 September 2015, for a total capital increase (including issuance premium)
of ?1,198,094.00.
Pursuant to the rules of the warrant exercise program of Galapagos' Executive
Committee adopted in 2013, Executive Committee members automatically are
committed to exercise a minimum number of warrants, subject to certain
conditions. Accordingly, CEO Onno van de Stolpe exercised 10,000 warrants and
two other Executive Committee members exercised an aggregate amount of 5,000
warrants.
In accordance with Belgian transparency legislation[1], Galapagos notes that its
total share capital currently amounts to ?211,045,322.22; the total number of
securities conferring voting rights is 39,012,842, which is also the total
number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 2,869,192, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have any
convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other indications.
Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, currently
in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos reported
good activity and a favorable safety profile in both the DARWIN 1 and 2 trials
in RA. In the field of cystic fibrosis, AbbVie and Galapagos signed a
collaboration agreement to develop and commercialize molecules that address
mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1
trial, and corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205,
a first-in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently
being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown
favorable safety in a Phase 1 trial and is expected to enter Phase 2 in
idiopathic pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More info at www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, VP Corporate Communications & IR
Tel: +1-781-460-1784
ir(at)glpg.com
Forward-looking statements
This release may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but are not always,
made through the use of words or phrases such as "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," "continues," "we believe," "we intend," as well as similar
expressions. Such forward-looking statements may involve known and unknown
risks, uncertainties and other factors which might cause the actual results,
financial condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions, performance or achievements expressed or implied by such
forward-looking statements. Among the factors that may result in differences are
the inherent uncertainties associated with competitive developments, clinical
trial and product development activities, regulatory approval requirements and
estimating the commercial potential of our product candidates. A further list
and description of these risks, uncertainties and other risks can be found in
the company's Securities and Exchange Commission filing and reports, including
in the company's prospectus filed with the SEC on May 14, 2015 and future
filings and reports by the company. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication of
this document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
regulation.
--------------------------------------------------------------------------------
[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in
issuers whose shares are admitted to trading on a regulated market
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1956421]
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2015 - 22:01 Uhr
Sprache: Deutsch
News-ID 424487
Anzahl Zeichen: 6451
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 170 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos raises ?1.2 million through warrant exercises"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
